- Home
- CZNC vs TNGX Comparison
CZNC vs TNGX Comparison
Compare CZNC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- TNGX
- Stock Information
- Founded
- CZNC 1864
- TNGX 2014
- Country
- CZNC United States
- TNGX United States
- Employees
- CZNC N/A
- TNGX N/A
- Industry
- CZNC Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- TNGX Health Care
- Exchange
- CZNC Nasdaq
- TNGX Nasdaq
- Market Cap
- CZNC 287.4M
- TNGX 351.2M
- IPO Year
- CZNC N/A
- TNGX N/A
- Fundamental
- Price
- CZNC $19.34
- TNGX $5.02
- Analyst Decision
- CZNC
- TNGX Strong Buy
- Analyst Count
- CZNC 0
- TNGX 6
- Target Price
- CZNC N/A
- TNGX $12.20
- AVG Volume (30 Days)
- CZNC 35.2K
- TNGX 4.0M
- Earning Date
- CZNC 08-06-2025
- TNGX 08-06-2025
- Dividend Yield
- CZNC 5.86%
- TNGX N/A
- EPS Growth
- CZNC 15.34
- TNGX N/A
- EPS
- CZNC 1.75
- TNGX N/A
- Revenue
- CZNC $108,114,000.00
- TNGX $40,990,000.00
- Revenue This Year
- CZNC $6.78
- TNGX N/A
- Revenue Next Year
- CZNC $4.59
- TNGX N/A
- P/E Ratio
- CZNC $10.97
- TNGX N/A
- Revenue Growth
- CZNC 5.33
- TNGX 10.09
- 52 Week Low
- CZNC $16.73
- TNGX $1.03
- 52 Week High
- CZNC $22.68
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- CZNC 55.28
- TNGX 69.44
- Support Level
- CZNC $18.60
- TNGX $4.70
- Resistance Level
- CZNC $19.26
- TNGX $5.63
- Average True Range (ATR)
- CZNC 0.48
- TNGX 0.60
- MACD
- CZNC 0.08
- TNGX -0.01
- Stochastic Oscillator
- CZNC 87.93
- TNGX 65.38
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.